WO2004012650A2 - Compositions cosmetiques ou dermopharmaceutiques comprenant du kombucha. - Google Patents
Compositions cosmetiques ou dermopharmaceutiques comprenant du kombucha. Download PDFInfo
- Publication number
- WO2004012650A2 WO2004012650A2 PCT/FR2003/002368 FR0302368W WO2004012650A2 WO 2004012650 A2 WO2004012650 A2 WO 2004012650A2 FR 0302368 W FR0302368 W FR 0302368W WO 2004012650 A2 WO2004012650 A2 WO 2004012650A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- kombucha
- cosmetic
- tea
- micro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to cosmetic or dermopharmaceutical compositions which contain kombucha and the use of kombucha and cosmetic or dermopharmaceutical compositions containing it, alone or in combination, for all care of the skin, mucous membranes and integuments, and in particular to prevent signs of endogenous and / or exogenous aging.
- the skin, mucous membranes, and integuments are fragile elements which deserve the greatest consideration. Indeed, their balance is permanently disturbed by external aggressions, sun, wind, cold.
- One of the first outward signs of aging is skin aging. It results from a number of alterations which occur spontaneously over time but which can also be induced by external factors (solar radiation, tobacco smoke, excessive consumption of alcohol).
- the signs of aging are clinically manifested by the appearance of fine lines and wrinkles, by sagging skin and subcutaneous tissues which results in dull skin texture, sagging skin micro-relief, reduced skin firmness, loss of elasticity, and overall loose skin, duller and dull.
- Aging also results in a decrease in the number, thickness and growth of hair, a decrease in secretions (sebaceous and sweat), and an alteration of the structure and growth of the nails. In areas of the skin that have been exposed to the sun throughout life - essentially the face, beaulleté, hands and forearms - spots of hyper- or hypopigmentation are often observed.
- Some of these signs are more particularly linked to intrinsic or physiological aging, that is to say aging linked to age, so that others are more specific to extrinsic aging, ie aging caused in general by the environment; this is more particularly photo-aging due to exposure to the sun, light or any other radiation.
- the present invention relates to the general treatment of aging of the skin, mucous membranes and appendages, in particular by improving the radiance of the complexion, and in particular by preventing or slowing down glycation, as well as by stimulation of lipid synthesis by skin adipocytes.
- the skin cells and in particular the collagen fibers which are the main constituent of the extracellular matrix
- the dermis becomes thinner, but the surface layer thickens through defective removal of dead cells.
- the invention which is the subject of this patent application therefore relates to a product having a strong anti-glycation power.
- glowing skin such as baby's skin
- skin that otherwise reflects light. It is smooth, with an improved, taut micro-relief.
- Restoring substance to the skin, redensifying the dermis, is therefore also a valid approach to fight against wrinkles and fine lines, to help the skin regain radiance and a more youthful appearance.
- One of the aims of the present invention is therefore to be able to propose a product which is effective against skin and hair aging in general and in particular against glycation and the reduction of subcutaneous lipids, and this without significant side effects.
- Green tea Many natural products, such as green tea, are already used in cosmetic products and claim to treat wrinkles and fine lines on the skin or firm skin tissue, restore radiance to the skin.
- these compositions treat these morphological disorders only incompletely and temporarily and their use is often not obvious.
- Green tea tends to darken finished products, and its activity is limited: the properties claimed for green tea are anti-radical protection and antioxidant activity, or even thinning when the tea extract green is dosed with caffeine.
- Kombucha in topical application, has interesting cosmetic activities which make it possible to fight against the signs of aging in a more specific way, fighting against glycation, and the various deficiencies of the metabolism of the skin, improving skin micro-relief.
- Kombucha is a tea that has undergone a microbiological transformation. This transformation is a fermentation by a yeast symbiont of the genus Saccharomyces which nests within a matrix of polysaccharides produced by a Bacterium Xylinum.
- this symbiosis (in particular the proportions of each species) varies with geographic and climatic conditions and depends on the local wild subspecies of yeast and bacteria; nevertheless, we can cite, among others, without this list being exhaustive: Saccharomyces ludwigii, Saccharomyces apicalutus species, Bacterium xylinoides, Bacterium gluconicum, Schizosaccharomyces pombe, Acetobacter ketogenum, Torula species, Pichia fermentans and other yeasts. In the kombucha literature, this yeast and bacteria symbiote is also called "fungus", "long life champion” and many synonyms.
- Yeast metabolism products are excreted in kombucha and are made up of many vitamins such as B1, B2, B3 and B12, co-factors essential for the growth of bacteria.
- Kombucha also called “long-lived mushroom tea” is a popular therapeutic remedy known for a long time by different names [FRANK G., 1999]. It is a refreshing drink in yellow-amber color with a sweet-acid taste of cider. Its effect has been known and appreciated for generations by many peoples, especially in the countries of East Asia.
- the tea used for making kombucha can be of any kind and from any origin, these include Camellia sinensis sinensis or assamica varieties. All varieties of green tea, semi-fermented tea, black tea, smoked black tea, yellow tea, dark tea, white tea, herbal tea with herbs or herbal tea, can be used as a basis for making kombucha. We preferentially use all varieties of green tea, semi-fermented tea, black tea, smoked black tea, yellow tea, dark tea, white tea (all Camellia sinsensis) and more particularly black tea.
- black tea is the best broth for cultivation: it leads to the highest concentration of lactic and gluconic acid, offers the best conditions for the growth of
- the “mushroom”, as well as the recipe for making kombucha, is passed on from generation to generation.
- the process for manufacturing kombucha is presented as an example to illustrate the present invention.
- kombucha in the present invention includes synonyms such as comboucha, cajnyj kvas (Russian), Combuchagetbasedk (German), Kargasoktee (German), komboecha-drank (Dutch), Kombuchakwa ⁇ (German), tea-beer and tea- cider (english), etc ...
- the symbiote, "long-lived mushroom” is also called, in particular: cajnyj grib ( Russian), Japanese or Chinese mushroom, miracle mushroom, comboucha, combucha (Japanese), fungojapon, fungus japonicus (pharmaceutical designation), funko cinese (italian), ganoderma japonicum, japanischer Teepilz (german), kombucha, ling zhi
- Kombucha produces, besides many substances with antibiotic effect which are difficult to define, above all glucuronic acid, vitamins B1, B2, B3, B6 and B12 as well as folic acid, and lactic acid D (+) .
- the object of this patent application lies in the discovery, and in the demonstration, that kombucha, suitably prepared and used, turns out to be a new solution to combat the signs of aging exposed previously.
- Kombucha is indeed rich in vitamins, amino acids, sugars, and epigallocatechin gallate (EGCG).
- kombucha boosts the activity of all skin cell types (keratinocytes, melanocytes, fibroblasts and adipocytes). It also boosts immune activity by stimulating Langherans cells, and the activity of adipocytes up to lipogenesis. Kombucha can therefore be considered as a restructuring agent against aging, by its nutritive activity.
- kombucha by topical application, stimulates lipid synthesis by cutaneous adipocytes. It is therefore capable of preventing and treating wrinkles and fine lines on the skin, firming the skin tissues of the face, hips, thighs, restoring radiance to the skin by improving the skin's micro-relief. .
- the kombucha is also capable of ensuring a better cutaneous irrigation, of regulating the activity of the melanocytes.
- the kombucha used in the cosmetic or dermopharmaceutical compositions which are the subject of this invention, can be manufactured from any source of tea, herbal tea, infusion, by fermentation using any combination of fungi, yeasts and bacteria, in particular those mentioned. upper.
- the topical application of kombucha has never been described.
- the present invention therefore relates to cosmetic or dermopharmaceutical compositions containing kombucha.
- compositions which are the subject of this invention contain a cosmetically or dermatologically acceptable medium, that is to say compatible with skin tissue. So the composition can be applied to the whole human body, including the mucous membranes and dander.
- the kombucha is used by way of example in an amount ranging from 0.001% (w / w) to 100% (w / w) of the total weight of the composition, preferably between 0.01% (w / w) and 20 % (w / w).
- compositions are, for example, lotions, milks or emollient creams, milks or creams for skin or hair care, creams, lotions or cleansing milks, foundations, foundations, lotions, suntan milks or creams, lotions, artificial tan oats or creams, shaving creams or foams, aftershave lotions, shampoos, lipsticks, mascaras or nail polishes.
- compositions can also be in the form of lip sticks intended either to color them or to avoid chapping, L5 or make-up products for the eyes or make-up and foundations for the face.
- the fatty phase essentially consists of a mixture of fatty substances of extraction or 0 synthesis, with at least one oil, and possibly another fatty substance.
- the fatty phase of the emulsions can constitute from 5 to 60% of the total weight of the expulsion.
- the aqueous phase of said emulsions preferably constitutes from 30 to 85% of the total weight of the emulsion.
- the proportion of the emulsifying agent 5 can be between 1 and 20%, and preferably between 2 and 12% of the total weight of the emulsion.
- the compositions according to the invention are in the form of oily, oleoalcoholic or hydroalcoholic lotions, they can constitute, for example, lotions sunscreens containing a filter absorbing UV rays, skin softening lotions; oily lotions can also constitute foaming oils containing an oil-soluble surfactant, oils for the bath, etc.
- organic or hydroglycolic solvents including MP-diol and polyglycerins, fatty substances for extraction or synthesis, ionic or nonionic thickeners , softeners, opacifiers, stabilizers, emollients, silicones, ⁇ - or ⁇ -hydroxy acids, anti-foaming agents, hydrating agents, vitamins, perfumes, preservatives, sequestrants, dyes, gelling and viscosifying polymers, surfactants and emulsifiers, other water- or liposoluble active ingredients, plant extracts, tissue extracts, marine extracts, sun filters, antioxidants.
- organic or hydroglycolic solvents including MP-diol and polyglycerins, fatty substances for extraction or synthesis, ionic or nonionic thickeners , softeners, opacifiers, stabilizers, emollients, silicones, ⁇ - or ⁇ -hydroxy acids, anti-foaming agents, hydrating agents, vitamins
- the mono-or poly-alcohols which are more particularly preferred are chosen from ethanol, isopropanol, propylene glycol, glycerol and sorbitol.
- Mention may be made, as fatty substance, of mineral oils, of petrolatum oil; among animal oils, whale, shark, seal, menhaden, halibut, cod, tuna, turtle, ox's foot, horse's foot, sheep's foot, mink's oils , otter, groundhog, etc ...; among vegetable oils, almond, wheat germ, jojoba, sesame, sunflower, palm, nut, shea, shorea, macadamia, blackcurrant seed and the like oils.
- fatty acid esters it is possible to use saturated or unsaturated C ⁇ 2 to C 22 acid esters and lower alcohols such as isopropanol or glycerol or linear C 8 to C 22l fatty alcohols or branched, saturated or unsaturated or alkanediols-1, 2 in C ⁇ 0 -C 22 . Mention may also be made, as fatty substance, of petroleum jelly, paraffin, lanolin, hydrogenated lanolin, tallow, acetylated lanolin, silicone oils.
- waxes mention may be made of Sipol wax, lanolin wax, beeswax, Candelila wax, monocrystalline wax, Carnauba wax, spermaceti, cocoa butter, shea butter, silicone waxes, hydrogenated oils concrete at 25 ° C, sucroglycerides, oleates, myristates, linoleates and stearates of calcium, magnesium and aluminum.
- fatty alcohols mention may be made of lauric, cetyl, myristic, stearic, palmitic, oleic alcohols and GUERBET alcohols such as 2-decyltetradecanol or 2-hexyldecanol.
- emulsifiers among the polyoxyethylenated fatty alcohols, mention may be made of lauric, cetyl, stearyl and oleic alcohols comprising from 2 to 20 moles of ethylene oxide and among the glycerol alkyl ethers, C 2 -C 8 alcohols comprising from 2 to 10 moles of glycerol. It may also be useful to use thickeners such as cellulose derivatives, polyacrylic acid derivatives, guar or carob gum or xanthan gum.
- compositions according to the invention can include other varied and additional ingredients, conventional or not.
- decision to include an ingredient and the choice of a specific active ingredient and additional ingredients depends on the specific application and formulation of the product.
- the dividing line between an "active ingredient and an” additional “ingredient is therefore artificial and depends on the specific application and the type of product.
- a substance which is an ingredient" active in an application or a product can be an ingredient " additional "or” functional "in another, and vice versa.
- compositions according to the present invention can therefore include one or more active ingredients, which will bring a certain advantage to the object. of the application of the composition, for example the skin or the hair.
- active ingredients can include one or more substances such as cleansing agents, hair care agents, skin care agent, styling agent, dandruff agent, hair regrowth agent, perfumes, sunscreens, pigments, moisturizers, agents film formers, hair dyes, make-up, detergents, thickening agents, emulsifiers, antiseptic agents, deodorant and surfactant active agents, propellants.
- active ingredient depends on the nature of the cosmetic or care product to be formulated. For example, sun filters can be used in sunscreen lotions, in shampoos, in hair care lotions, and so on. For each type of asset, one or more ingredients may be present. Likewise, more than one type of active ingredient can be present in a composition.
- the CTFA Cosmetic Ingredient Handbook, Ninth Edition (2002) lists many of the cosmetic ingredients usually used in the cosmetic industry, which are suitable for use in the compositions according to the present invention.
- ingredient classes include: abrasives, absorbents, essential oils, astringents, anti-caking agents, anti-foam agents, anti-microbial agents, antioxidants, binders, biologic additives, buffers, bulking agents, chelating agents, chemical additives, dyes, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film-forming agents, opacifying agents, pH, propellants, reducing agents, sequestrants, skin care agents (for example humectants), skin treatment agents, thickeners, but also the active ingredients taken from the consistent group of active ingredients desquamation, anti-acne active ingredients, vitamin C and its derivatives, vitamins B1 to B12 their derivatives, vitamin E and its derivatives, vitamin H, vitamin K, vitamin A and retinoids, peptides, hydroxy acids, anti-oxidants, radical scavengers, chelating agents, anti-inflammatory active agents, bronzing active agents,
- anti-microbial agents anti-wrinkle active agents, active agents stimulating lipolysis, active agents stimulating lipogenesis, anti-stress agents, proteolysis inhibitors, in particular MMP inhibitors, enzymes, ceramides and their analogues, anti-irritants and skin softening active agents, anti-pollution active agents, healing active agents, moisturizers,
- UV firming active ingredients, liposomes.
- hair care ingredients which can be combined in the compositions according to the present invention can be found on www.sederma.fr, or in the following paragraphs.
- compositions according to the present invention can also contain a sufficient quantity of anti-acne active agents.
- anti-acne active ingredients include the composition called ac.net® (marketed by SEDERMA, France) and its individual components (nordihydroguaiaretic acid, oleanolic acid), and also resorcinol, sulfur, salicylic acid, 0 benzoyl peroxide, erythromycin, zinc, etc.
- ac.net® marketed by SEDERMA, France
- resorcinol sulfur, salicylic acid, 0 benzoyl peroxide, erythromycin, zinc, etc.
- Other examples of anti-acne assets are described in detail in U.S. Pat. No. 5,607,980, issued to McAtee et al., March 4, 1997.
- compositions according to the present invention can also contain a sufficient amount of one or more anti-wrinkle active agents.
- anti-wrinkle active agents suitable for use in the compositions according to the present invention include alpha-hydroxy acids such as lactic acid and glycolic acid or beta-hydroxy acids such as salicylic acid and its derivatives, vitamins, especially vitamin B3 and all retinoids. Isoflavones and phytosterols are also suitable
- Peptides and in particular di-, tri-, tetra-, and pentapeptides and their derivatives can be included in the compositions according to the present invention in sufficient quantity.
- Peptides can be natural or synthetic.
- the dipeptides can be, without being limited to this list, Tyr-Arg, Val-Trp, Asn-Phe, Asp-Phe, beta-Ala-His (Camosine), N- palmitoyl-beta-Ala-His, Tyr-Arg -hexadecylester, and their derivatives.
- Tripeptides include Gly-His-Lys, Arg-Lys-Arg, His-Gly-Gly, Lys-Phe-Lys, Lys-Phe-Lys and their conservative substitution analogs, Gly-His-Lys, Gly-Lys-His , Arg-Lys-Arg-NH 2) and their derivatives. Tetrapeptides include Gly-GIn-Pro-Arg (Rigin), Thr-Lys-Pro-Arg (Tuftsin) Lys-Asn-Pro-Tyr, Lys-
- Pentapeptides and hexapeptides can be, but are not limited to this list, Lys-Thr-Thr-Lys-
- peptides will be used in their free or N-acylated forms.
- a preferred dipeptide is N-Ac-Tyr-Arg-hexadecylester (CALMOSENSINE® from SEDERMA, France).
- a preferred tripeptide is N-palmitoyl-Gly-His-Lys (BIOPEPTIDE CL from
- Peptide CK (Arg-Lys-Arg) and Lipospondine (N- elaidoyl-Lys-Phe-Lys) and its conservative substitution analogs, Peptide CK + (N-Ac-Arg-Lys-Arg- NH 2 ).
- a preferred tetrapeptide is N-palmitoyl-Gly-GIn-Pro-Arg and a preferred pentapeptide is N-Pal-Lys-Thr-Thr-Lys-Ser, available under the name MATRIXYL® from SEDERMA, France.
- compositions according to the present invention can include antioxidants and / or radical scavengers to protect the skin from damage caused by exposure to U V.
- Antioxidants / radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbic esters of fatty acids, ascorbic acid derivatives (e.g.
- the flavonoids suitable for the present invention are the flavanones chosen from unsubstituted flavanones, monosubstituted flavanones, and mixtures thereof; chalcones selected from unsubstituted chalcones, mono-substituted chalcones, di-substituted chalcones, tri-substituted chalcones, and mixtures thereof; flavones selected from unsubstituted flavones, mono-substituted flavones, di-substituted flavones, and mixtures thereof; one or more isoflavones; coumarins selected from unsubstituted coumarins, mono-substituted coumarins, di-substituted coumarins, and mixtures thereof; the chromones chosen from unsubstituted chromones, mono-substituted chromones, di-substituted chromones
- flavonoids can be found in PCT application No. WO 00/62743 filed by Larry R. Robinson et al. April 19, 2000, published October 26, 2000. They can be obtained as extracts from natural sources (plants, algae), as hemisynthesis or synthesis products. Mixtures of the above flavonoid compounds can also be used.
- compositions according to the present invention may contain a skin lightening agent.
- Skin lightening agents include kojic acid, arbutin, ascorbic acid and its derivatives (especially magnesium ascorbyl phosphate or sodium ascorbyl phosphate), and extracts (especially citrus unshiu extract, noraporphine derivatives, extracts of bearberry and mitracarpus, respectively available as MELASLOW®, LUMISKIN® and ETIOLINE® from SEDERMA, France).
- Anti-inflammatory agents can be incorporated into compositions according to the present invention, such as natural extracts of plants, fungi, algae.
- ursolic acid, nordihydroguaiaretic acid, kava-kava extract, bacopa monnieri extract (BACOCALMINE® from SEDERMA, France) candelilla wax, bisabolol, aloe vera, plant sterols, chamomile, red clover extract (sold under the name STEROCARE® from SEDERMA, France), and sea whip extracts can be used.
- Suitable anti-inflammatory agents include compounds of the licorice family (of the genus / species Glycvrrhiza glabra), including glycyrrhetic acid, glycyrrhizic acid, and their derivatives (including their salts and esters).
- compositions according to the invention are dispersions, they may be dispersions of lecithin in water in the presence of surfactant or alternatively aqueous dispersions of lipid spherules, consisting of organized molecular layers enclosing an aqueous phase encapsulated.
- lipid compounds long chain alcohols and diols
- sterols such as cholesterol, phospholipids, eholesteryl sulfate and phosphate, long chain amines and their quaternary ammonium derivatives, dihydroxyalkylamines, polyoxyethylenated fatty amines, esters of long-chain amino alcohols, their salts and quaternary ammonium derivatives, phosphoric esters of fatty alcohols such as acid diketylphosphate or its sodium salt, alkylsulphates such as cetylsulphate sodium, fatty acids in the form of salts or lipids of the type described in French patents 2,315,991, 1,477,048 and 2,091,516 or in international patent applications WO 83/01 571 and WO 92 / 08,685.
- lipids comprising a long lipophilic chain containing 12 to 30 carbon atoms, saturated or unsaturated, branched or linear, for example an oleic, lanolic, tetradecylic, hexadecylic, isostearyl, lauric or alkylphenyl chain.
- the hydrophilic group of these lipids can be an ionic or nonionic group.
- nonionic groups mention may be made of groups derived from polyethylene glycol.
- polyglycerol ethers such as those described in French patents No. 1,477,048, 2,091,516, 2,465,780 and 2,482,128.
- ionic group it is advantageous to use a group derived from an amphoteric, anionic or cationic compound.
- lipids described in international patent application WO 83/01 571 as being able to be used for the formation of vesicles are the glycolipids such as lactosylceramide, galactocerebroside, gangliosides and trihexosylceramide, as well as phospholipids such as phosphatidylglycerol and phosphatidylinositol. -Lo
- the active substances can be substances having a pharmaceutical or food interest or having a cosmetic activity. When they are water-soluble, they can be dissolved homogeneously or they are in the aqueous phase encapsulated inside the vesicles.
- the water-soluble substances having a cosmetic and / or pharmaceutical activity can be products intended for the care or treatment of the skin and the hair such as for example humectants such as glycerin, sorbitol, pentaerythritol, pyrrolidone carboxylic acid and its salts; artificial browning agents such as dihydroxyacetone, erythrulose, glyceraldehyde, ⁇ ⁇ dialdehydes such as tartaric aldehyde, these compounds being possibly associated with dyes; water-soluble sun filters; antiperspirants, deodorants, astringents, refreshing, tonic, healing, keratolytic, depilatory, scented waters; plant tissue extracts, such as polysaccharides; water-
- the active substances are liposoluble, they can be incorporated into the sheets of the vesicles. They can be chosen from the group formed by liposoluble sun filters, substances intended to improve the condition of dry or senile skin, tocopherols, vitamins E, F or A and their esters, retinoic acid, antioxidants, essential fatty acids, glycyrrhetinic acid, keratolytics and carotenoids. Kombucha can be used in cosmetic compositions according to the invention either as an individual addition or as a premix in a suitable excipient, and used in the form of a solution, dispersion, emulsion, paste or powder.
- cosmetic vectors such as macro-, micro- or nanocapsules, liposomes or chylomicrons, macro-, micro- or nanoparticles or micro-sponges. It can also be adsorbed on powdery organic polymers, talcs, bentonites and other mineral supports.
- the present invention also relates to the use of kombucha and the use of cosmetic and dermopharmaceutical compositions containing it, alone or in combination, as or for the manufacture of cosmetic or dermopharmaceutical compositions for all care of the skin, mucous membranes, and integuments, in particular to prevent the signs of endogenous and / or exogenous aging, and in particular to restore suppleness and elasticity to the skin, improve its appearance and the feeling of comfort, perform a cosmetic "lipofilling", firm the skin of the face, hips, thighs, tone the texture of the skin, restore material to the skin, rediscover the full forms of a young face, redensify, revive the radiance of the skin, increase radiance.
- the present invention also relates to the use of kombucha and the use of cosmetic and dermopharmaceutical compositions containing it, alone or in combination, as or for the manufacture of cosmetic or dermopharmaceutical compositions for treating in particular wrinkles and / or fine lines. , sagging skin and / or subcutaneous skin of the face, hips, thighs, slackening (or collapse) of skin micro-relief, saggy skin, dull skin.
- the present invention also relates to the use of kombucha, alone or incorporated in cosmetic or dermopharmaceutical compositions for the preparation of medicaments intended for the care of the skin, mucous membranes and integuments, particularly for combating the signs of endogenous aging and / or exogenous.
- Example 1 Making kombucha
- a wide-opening glass container leave to ferment sweet tea, containing at least 5 g of tea (black for example) per liter and at least 70 g of sugar per liter, with the symbiote, for example "long mushroom life with kombucha ”available from the company R. FRANK (in Birkenfeld in Germany), of which a piece of about 25 to 100 g / l is added to the sweet tea. Place the fermentation container in a warm place for several (5 to 12) days. After filtration the kombucha is ready, and the "mushroom” is recovered for the next fermentation. It is possible in the manufacture of kombucha to add to the mixture of sweet tea and mushroom, 10% of kombucha obtained during a previous production, in order to more easily initialize the fermentation.
- Example 2 iour cream ⁇ / 100 ⁇
- This emulsion is used to illuminate and redensify the facial skin.
- Example No. 6 Anti-qlvcation Effectiveness Principle: An in vitro model system, consisting of serum albumin incubated in the presence of fructose, is incubated for 3 weeks. Glycation is observed by the formation of fluorescent compounds, generally pentosides or FFIs (furoyl-furanyl-imidazoles). Protocol: The non-enzymatic glycation between serum albumin and fructose is a spontaneous and slow reaction, it can be accelerated by temperature.
- FFIs furoyl-furanyl-imidazoles
- albumin serum (2%) and fructose at 100 mM are incubated in phosphate buffer medium pH 7.4 at 50 ° C for 1 week.
- the reference value (control) for glycation after 1 week is established on the incubate serum albumin and fructose.
- the positive glycation inhibition control is obtained by incubation in the presence of 0.03% aminoguanidine, and the test incubations are carried out in the presence of kombucha at different concentrations.
- a very strong anti-glycation activity is also observed, with no significant dose effect, with a reduction of - 71% and - 79% respectively of the EFAs formed in the presence of kombucha at 1 and 3%.
- the culture takes place in 3 stages: a first stage of cell multiplication until confluence, a second stage after addition of the differentiation cocktail to obtain initial pre-adipocytes (72 hours), and finally the third stage of active differentiation with stimulation of lipogenesis (72 hours): the apparent storage in lipid droplets is then clearly visible under the microscope.
- G3PDH Glycerol-3-Phosphodehydrogenase
- the G3PDH activity is compared between the control pre-adipocytes and those incubated in the presence of the test product.
- An increase in G3PDH activity is expected for a product promoting differentiation.
- Protocol At the end of the differentiation caused (72 hours), the media are renewed without the differentiating cocktail but with kombucha at different concentrations. The pre-adipocytes therefore remain in contact with the kombucha for 6 days.
- the cells At the end of incubation, the cells are removed and lysed and the enzymatic activity test is carried out on the intracellular content.
- Table 2 Stimulation of differentiation of adipocytes in culture: increase in G3PDH activity of preadipocytes treated with kombucha at different concentrations.
- Kombucha increases G3PDH activity in a dose-dependent manner. The increase is very significant and reaches 136% when kombucha is used at 3%. The increased activity of G3PDH reflects the stimulating power of kombucha on adipocyte differentiation.
- Morphological observation on pre-adipocytes The morphology of the cells under the microscope, at the end of the incubation period in the presence of kombucha, shows a richer and differentiated adipocyte population with lipid inclusions compared to the control cells.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/523,333 US20060165643A1 (en) | 2002-07-30 | 2003-07-25 | Cosmetic or dermopharmaceutical compositions containing kombucha |
JP2004525474A JP4099173B2 (ja) | 2002-07-30 | 2003-07-25 | コンブチャ(kombucha)を含む化粧品または皮膚用薬組成物 |
AU2003274205A AU2003274205A1 (en) | 2002-07-30 | 2003-07-25 | Cosmetic or dermopharmaceutical compositions containing kombucha |
EP03758186A EP1555999B1 (fr) | 2002-07-30 | 2003-07-25 | Utilisation cosmétique du kombucha pour lutter contre le vieillissement de la peau |
US12/231,114 US20090010976A1 (en) | 2002-07-30 | 2008-08-29 | Cosmetic or dermopharmaceutical compositions containing kombucha |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/09710 | 2002-07-30 | ||
FR0209710A FR2843023B1 (fr) | 2002-07-30 | 2002-07-30 | Compositions cosmetiques ou dermopharmaceutiques contenant du kombucha. |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/231,114 Division US20090010976A1 (en) | 2002-07-30 | 2008-08-29 | Cosmetic or dermopharmaceutical compositions containing kombucha |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004012650A2 true WO2004012650A2 (fr) | 2004-02-12 |
WO2004012650A3 WO2004012650A3 (fr) | 2004-04-15 |
Family
ID=30129562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/002368 WO2004012650A2 (fr) | 2002-07-30 | 2003-07-25 | Compositions cosmetiques ou dermopharmaceutiques comprenant du kombucha. |
Country Status (6)
Country | Link |
---|---|
US (2) | US20060165643A1 (fr) |
EP (1) | EP1555999B1 (fr) |
JP (1) | JP4099173B2 (fr) |
AU (1) | AU2003274205A1 (fr) |
FR (1) | FR2843023B1 (fr) |
WO (1) | WO2004012650A2 (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1486201A1 (fr) * | 2003-06-09 | 2004-12-15 | Nihon Kolmar Co., Ltd. | Base cosmétique comprenant des extraits de Schizosaccharomyces |
KR100466623B1 (ko) * | 2002-01-17 | 2005-01-15 | 주식회사 에스티씨나라 | 피부재생 및 피부 노화지연 효과를 가지는 콤부차 발효배양액 및 이를 함유하는 조성물 |
FR2865399A1 (fr) * | 2004-01-26 | 2005-07-29 | Greentech Sa | Utilisation de l'extrait de kombucha dans des preparations pharmaceutiques ou cosmetiques pour des applications galbantes, tenseurs et raffermissantes des seins |
EP2055307A1 (fr) * | 2007-11-01 | 2009-05-06 | Beiersdorf AG | Combinaisons de matières actives constituées d'un extrait de fruit anisé et d'un extrait de thé blanc |
US8361516B2 (en) | 2006-08-03 | 2013-01-29 | Sederma | Composition comprising sarsasapogenin |
US8404648B2 (en) | 2006-02-16 | 2013-03-26 | Sederma | Polypeptides KXK and their use |
FR2982487A1 (fr) * | 2011-11-14 | 2013-05-17 | Oreal | Utilisation d'une association de trois principes actifs pour la reconstruction du tissu adipeux et la lutte contre les signes du vieillissement cutane |
US8507649B2 (en) | 2006-05-05 | 2013-08-13 | Sederma | Cosmetic compositions comprising at least one peptide with at least one immobilized aromatic cycle |
WO2014080376A2 (fr) | 2012-11-26 | 2014-05-30 | Sederma | Peptides pro-pigmentants |
WO2015181688A1 (fr) | 2014-05-22 | 2015-12-03 | Sederma | Peptides, compositions les comprenant et utilisations, en particulier utilisations cosmétiques |
WO2016097966A1 (fr) | 2014-12-16 | 2016-06-23 | Sederma | Tripeptides, compositions les contenant et leurs utilisations cosmétiques |
WO2016097965A1 (fr) | 2014-12-16 | 2016-06-23 | Sederma | Composés peptidiques, compositions les comprenant et utilisations desdits composés, en particulier leurs utilisations cosmétiques |
WO2016113659A1 (fr) | 2015-01-13 | 2016-07-21 | Sederma | Utilisation de cellules de plante de leontopodium alpinum pour un traitement cosmétique et substance active correspondante |
RU2641276C2 (ru) * | 2015-12-29 | 2018-01-16 | Людмила Дмитриевна Тимченко | Способ производства основы биодеградируемого покрытия |
FR3131215A1 (fr) * | 2021-12-23 | 2023-06-30 | L V M H Recherche | Extrait fermenté d’écorces de fruits de mangoustan |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2836042B1 (fr) * | 2002-02-15 | 2004-04-02 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques pour diminuer les poches et cernes sous les yeux |
FR2843023B1 (fr) * | 2002-07-30 | 2004-09-24 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques contenant du kombucha. |
FR2869229B1 (fr) * | 2004-04-26 | 2006-08-25 | Sederma Soc Par Actions Simpli | Utilisation d'un inducteur des ugt par voie topique |
FR2880802B1 (fr) * | 2005-01-14 | 2008-12-19 | Sederma Soc Par Actions Simpli | Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene |
FR2885522B1 (fr) * | 2005-05-13 | 2020-01-10 | Sederma | Composition cosmetique ou dermopharmaceutique contenant de la teprenone |
FR2890310B1 (fr) | 2005-09-06 | 2009-04-03 | Sederma Soc Par Actions Simpli | Utilisation des protoberberines comme agents regulant l'activite de l'unite pilosebacee |
US20100021401A1 (en) * | 2006-10-10 | 2010-01-28 | Liliane Sallander | Method for treating skin |
FR2913598B1 (fr) * | 2007-03-12 | 2009-10-09 | Oreal | Utilisation de derives c-glycosides pour diminuer la visibilite des pores de la peau |
DE102007052534A1 (de) * | 2007-11-01 | 2009-05-07 | Beiersdorf Ag | Kosmetische Verwendung von weißem Teeextrakt zur Bräunung der Haut |
CA2689472C (fr) * | 2008-07-18 | 2019-01-15 | Karine Theberge | Articles de fabrication liberant un ingredient actif |
KR101142977B1 (ko) | 2009-10-22 | 2012-05-08 | 주식회사 코스메카코리아 | 백련오행차 혼합 추출물을 함유하는 아토피 피부 개선 효과를 가지는 화장료 조성물 및 그 제조방법 및 그를 함유하는 화장료 |
US20120035557A1 (en) | 2010-07-16 | 2012-02-09 | Timothy Woodrow Coffindaffer | Personal Care Compositions Comprising A Multi-Active System For Down Regulating Cytokines Irritation |
US8435541B2 (en) | 2010-09-02 | 2013-05-07 | Bath & Body Works Brand Management, Inc. | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities |
FR2968990B1 (fr) * | 2010-12-17 | 2013-02-22 | Oreal | " utilisation de population microbienne stable comme agent pour stimuler la regeneration epidermique de la peau suite a un traitement cosmetique de nature chimique et/ou mecanique et/ou physique" |
WO2013025893A1 (fr) | 2011-08-16 | 2013-02-21 | The Gillette Company | Compositions de soins personnels comprenant un agent anti-irritation |
FR2979541B1 (fr) * | 2011-09-05 | 2013-10-04 | Silab Sa | Principe actif issu de torulaspora delbrueckii et utilisation cosmetique pour ameliorer et/ou reparer la fonction barriere de la peau |
EP2596776A1 (fr) * | 2011-11-25 | 2013-05-29 | Micuri ApS | Composition probiotique emballée et utilisations associées |
KR101350292B1 (ko) | 2012-04-12 | 2014-01-13 | 주식회사 한국화장품제조 | 천삼, 녹각영지, 백호은침으로 구성된 발효 추출물을 유효 성분으로 하는 화장료 조성물 및 이의 제조 방법 |
US9877494B2 (en) * | 2014-08-21 | 2018-01-30 | Shantung HSU | Active fermentation process and fermented liquid and drinks made by using the same |
KR101485896B1 (ko) * | 2014-10-27 | 2015-01-26 | 주식회사 더트루메틱 | 홍차 발효액을 유효성분으로 하는 항산화, 항염증 및 아토피 개선용 화장료 조성물 및 그의 제조방법 |
HUP1600097A2 (en) * | 2016-02-18 | 2017-09-28 | Hummel Zoltan Dr | Process for high-efficiency water supply of intestinal flora in the colon |
RU2646468C1 (ru) * | 2017-08-10 | 2018-03-05 | Анастасия Владимировна Серебрянская | Косметический и/или оздоровительный биологически активный препарат |
RU2665948C1 (ru) * | 2017-08-22 | 2018-09-05 | Анастасия Владимировна Серебрянская | Лекарственный препарат для наружного применения |
CN110538102A (zh) * | 2018-05-29 | 2019-12-06 | 伽蓝(集团)股份有限公司 | 大吉岭红茶提取物的应用 |
CN113382719B (zh) | 2018-12-11 | 2023-10-31 | 迪斯拉普申实验室公司 | 用于递送治疗剂的组合物及其使用方法和制备方法 |
CN110721136A (zh) * | 2019-12-02 | 2020-01-24 | 江苏巴帝恩生物科技有限公司 | 一种含有康普茶的化妆品原料的制备方法及其应用 |
CN111297790B (zh) * | 2020-02-25 | 2023-02-17 | 暨南大学 | 茶叶外囊泡的应用 |
EP4168900A1 (fr) * | 2020-06-17 | 2023-04-26 | Disruption Labs Inc. | Compositions pour compléter des produits avec des agents thérapeutiques et leurs procédés d'utilisation |
KR20240009458A (ko) | 2021-05-17 | 2024-01-22 | 아쿠아컬쳐드 푸즈 인크 | 박테리아와 균류의 공동 배양물을 포함하는 식품 |
FR3130515A1 (fr) * | 2021-12-16 | 2023-06-23 | Institut National Polytechnique De Toulouse | Procédé de préparation d’un marc de raisin fermenté, marc de raisin fermenté ainsi obtenu et son utilisation dans des compléments alimentaires ou dans des cosméceutiques. |
CN116445306B (zh) * | 2023-06-15 | 2023-09-01 | 山东锦鲤生物工程有限公司 | 粟酒裂殖酵母及其改善皮肤状况的应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU60900A1 (fr) * | 1970-05-12 | 1972-02-10 | ||
JPH06321763A (ja) * | 1993-05-17 | 1994-11-22 | Kao Corp | 美白剤 |
JPH07258061A (ja) * | 1994-03-16 | 1995-10-09 | Media:Kk | しわたるみ消失化粧用材料 |
US5653970A (en) * | 1994-12-08 | 1997-08-05 | Lever Brothers Company, Division Of Conopco, Inc. | Personal product compositions comprising heteroatom containing alkyl aldonamide compounds |
US5607980A (en) * | 1995-07-24 | 1997-03-04 | The Procter & Gamble Company | Topical compositions having improved skin feel |
WO1998011900A2 (fr) * | 1996-09-18 | 1998-03-26 | Sarill William J | Compositions contenant de la cobalamine et des acides amines |
US5962015A (en) * | 1997-05-02 | 1999-10-05 | Kobo Products S.A.R.L. | Stabilized liposomes |
DE19824727A1 (de) * | 1998-06-03 | 1999-12-09 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Catechinen oder einem Gehalt an Extrakt von grünem Tee |
US6309126B1 (en) * | 1999-10-21 | 2001-10-30 | Dipak Narula | Lotion application device |
JP2001181170A (ja) * | 1999-12-24 | 2001-07-03 | Kose Corp | 皮膚外用剤 |
JP4139545B2 (ja) * | 2000-03-17 | 2008-08-27 | 花王株式会社 | 皮膚化粧料 |
JP3449967B2 (ja) * | 2000-06-06 | 2003-09-22 | 株式会社ノエビア | 皮膚外用剤 |
FR2821086B1 (fr) * | 2001-02-21 | 2003-12-12 | Sederma Sa | Procede de fabrication de proteines par fermentation de microorganismes de la famille thermus, melange de proteines ainsi obtenu et composition cosmetique les contenant |
FR2830195B1 (fr) * | 2001-10-03 | 2004-10-22 | Sederma Sa | Compositions cosmetiques et dermopharmaceutiques pour les peaux a tendance acneique |
FR2836042B1 (fr) * | 2002-02-15 | 2004-04-02 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques pour diminuer les poches et cernes sous les yeux |
FR2841550B1 (fr) * | 2002-06-26 | 2007-05-04 | Sederma Sa | Nouvelles molecules derivees de la tyramine, leur mode de preparation, et leur utilisation seules ou associees dans des compositions cosmetiques ou dermopharmceutiques |
FR2843023B1 (fr) * | 2002-07-30 | 2004-09-24 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques contenant du kombucha. |
FR2854897B1 (fr) * | 2003-05-12 | 2007-05-04 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane. |
EP1648403B1 (fr) * | 2003-05-20 | 2012-08-15 | Sederma | Composition cosmetique amincissante contenant du cafestol ou du kahweol |
FR2869229B1 (fr) * | 2004-04-26 | 2006-08-25 | Sederma Soc Par Actions Simpli | Utilisation d'un inducteur des ugt par voie topique |
FR2880802B1 (fr) * | 2005-01-14 | 2008-12-19 | Sederma Soc Par Actions Simpli | Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene |
US20060067905A1 (en) * | 2005-04-01 | 2006-03-30 | Sederma Sas | Formulations and method for treating baldness |
ATE524486T1 (de) * | 2005-04-27 | 2011-09-15 | Sederma S A S | Lys-thr-dipeptide und deren verwendung |
FR2885522B1 (fr) * | 2005-05-13 | 2020-01-10 | Sederma | Composition cosmetique ou dermopharmaceutique contenant de la teprenone |
FR2890310B1 (fr) * | 2005-09-06 | 2009-04-03 | Sederma Soc Par Actions Simpli | Utilisation des protoberberines comme agents regulant l'activite de l'unite pilosebacee |
WO2007093839A1 (fr) * | 2006-02-16 | 2007-08-23 | Sederma | Nouveaux polypeptides kxk et leurs applications |
FR2900573B1 (fr) * | 2006-05-05 | 2014-05-16 | Sederma Sa | Nouvelles compositions cosmetiques renfermant au moins un peptide contenant au moins un cycle aromatique bloque |
FR2904549B1 (fr) * | 2006-08-03 | 2012-12-14 | Sederma Sa | Composition comprenant de la sarsasapogenine |
FR2920967B1 (fr) * | 2007-09-14 | 2009-10-23 | Sederma Soc Par Actions Simpli | Utilisation de l'hydroxymethionine en tant qu'actif anti age |
FR2927801B1 (fr) * | 2008-02-22 | 2010-03-05 | Sederma Sa | Composition cosmetique hydratante comprenant une combinaison d'homarine et d'erythritol |
-
2002
- 2002-07-30 FR FR0209710A patent/FR2843023B1/fr not_active Expired - Lifetime
-
2003
- 2003-07-25 EP EP03758186A patent/EP1555999B1/fr not_active Expired - Lifetime
- 2003-07-25 US US10/523,333 patent/US20060165643A1/en not_active Abandoned
- 2003-07-25 JP JP2004525474A patent/JP4099173B2/ja not_active Expired - Lifetime
- 2003-07-25 WO PCT/FR2003/002368 patent/WO2004012650A2/fr active Application Filing
- 2003-07-25 AU AU2003274205A patent/AU2003274205A1/en not_active Abandoned
-
2008
- 2008-08-29 US US12/231,114 patent/US20090010976A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100466623B1 (ko) * | 2002-01-17 | 2005-01-15 | 주식회사 에스티씨나라 | 피부재생 및 피부 노화지연 효과를 가지는 콤부차 발효배양액 및 이를 함유하는 조성물 |
EP1486201A1 (fr) * | 2003-06-09 | 2004-12-15 | Nihon Kolmar Co., Ltd. | Base cosmétique comprenant des extraits de Schizosaccharomyces |
FR2865399A1 (fr) * | 2004-01-26 | 2005-07-29 | Greentech Sa | Utilisation de l'extrait de kombucha dans des preparations pharmaceutiques ou cosmetiques pour des applications galbantes, tenseurs et raffermissantes des seins |
US8404648B2 (en) | 2006-02-16 | 2013-03-26 | Sederma | Polypeptides KXK and their use |
US8507649B2 (en) | 2006-05-05 | 2013-08-13 | Sederma | Cosmetic compositions comprising at least one peptide with at least one immobilized aromatic cycle |
US8361516B2 (en) | 2006-08-03 | 2013-01-29 | Sederma | Composition comprising sarsasapogenin |
EP2055307A1 (fr) * | 2007-11-01 | 2009-05-06 | Beiersdorf AG | Combinaisons de matières actives constituées d'un extrait de fruit anisé et d'un extrait de thé blanc |
FR2982487A1 (fr) * | 2011-11-14 | 2013-05-17 | Oreal | Utilisation d'une association de trois principes actifs pour la reconstruction du tissu adipeux et la lutte contre les signes du vieillissement cutane |
WO2013072322A1 (fr) | 2011-11-14 | 2013-05-23 | L'oreal | Utilisation d'une association de trois principes actifs pour la reconstruction du tissu adipeux et la lutte contre les signes du vieillissement cutané |
WO2014080376A2 (fr) | 2012-11-26 | 2014-05-30 | Sederma | Peptides pro-pigmentants |
US10231917B2 (en) | 2012-11-26 | 2019-03-19 | Sederma | Pro-pigmenting peptides |
EP4198041A2 (fr) | 2012-11-26 | 2023-06-21 | Sederma | Peptides cosmetiques |
US11324687B2 (en) | 2012-11-26 | 2022-05-10 | Sederma | Pro-pigmenting peptides |
US10660839B2 (en) | 2012-11-26 | 2020-05-26 | Sederma | Pro-pigmenting peptides |
US9534015B2 (en) | 2012-11-26 | 2017-01-03 | Sederma | Pro-pigmenting peptides |
WO2015181688A1 (fr) | 2014-05-22 | 2015-12-03 | Sederma | Peptides, compositions les comprenant et utilisations, en particulier utilisations cosmétiques |
US10668000B2 (en) | 2014-05-22 | 2020-06-02 | Sederma | Peptides, compositions comprising them and uses in particular cosmetic uses |
WO2016097965A1 (fr) | 2014-12-16 | 2016-06-23 | Sederma | Composés peptidiques, compositions les comprenant et utilisations desdits composés, en particulier leurs utilisations cosmétiques |
US11612556B2 (en) | 2014-12-16 | 2023-03-28 | Sederma | Peptidic compounds, compositions comprising them and uses of said compounds, in particular cosmetic uses |
WO2016097966A1 (fr) | 2014-12-16 | 2016-06-23 | Sederma | Tripeptides, compositions les contenant et leurs utilisations cosmétiques |
WO2016113659A1 (fr) | 2015-01-13 | 2016-07-21 | Sederma | Utilisation de cellules de plante de leontopodium alpinum pour un traitement cosmétique et substance active correspondante |
RU2641276C2 (ru) * | 2015-12-29 | 2018-01-16 | Людмила Дмитриевна Тимченко | Способ производства основы биодеградируемого покрытия |
FR3131215A1 (fr) * | 2021-12-23 | 2023-06-30 | L V M H Recherche | Extrait fermenté d’écorces de fruits de mangoustan |
Also Published As
Publication number | Publication date |
---|---|
EP1555999B1 (fr) | 2012-08-29 |
FR2843023A1 (fr) | 2004-02-06 |
AU2003274205A1 (en) | 2004-02-23 |
US20060165643A1 (en) | 2006-07-27 |
JP4099173B2 (ja) | 2008-06-11 |
FR2843023B1 (fr) | 2004-09-24 |
US20090010976A1 (en) | 2009-01-08 |
EP1555999A2 (fr) | 2005-07-27 |
AU2003274205A8 (en) | 2004-02-23 |
JP2005534691A (ja) | 2005-11-17 |
WO2004012650A3 (fr) | 2004-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1555999B1 (fr) | Utilisation cosmétique du kombucha pour lutter contre le vieillissement de la peau | |
EP1638991B1 (fr) | Composition cosmetique ou dermopharmaceutique pour reduire les signes du vieillissement cutane | |
EP1534682B1 (fr) | Nouvelles molecules derivees de la noraporphine | |
FR2980362A1 (fr) | Nouvelle utilisation cosmetique d'un extrait d'albizia julibrissin et composition topique correspondante | |
EP1001740B1 (fr) | Utilisation du ginsenoside rb1 pour stimuler la synthese de l'elastine | |
FR2929511A1 (fr) | Nouveau principe actif stimulant la proliferation et/ou l'activite des fibroblastes. | |
FR2985424A1 (fr) | Nouvelle utilisation topique de la zerumbone | |
FR2970868A1 (fr) | Extrait d'origine vegetale, composition le contenant, procede d'obtention par culture vegetale et utilisations dans les domaines cosmetique, pharmaceutique et cosmeceutique | |
EP1003538B1 (fr) | Utilisation d'extraits de polygonatum pour stimuler la synthese de l'elastine cutanee | |
FR2997299A1 (fr) | Association d'extraits de plantes, ingredient actif cosmetique et composition les contenant, et utilisation topique cosmetique | |
CA2303141A1 (fr) | Utilisation d'au moins un extrait du genre chrysanthemum pour favoriser la pigmentation de la peau et/ou des cheveux | |
FR2744915A1 (fr) | Composition cosmetique a base de cellules indifferenciees de ginkgo biloba | |
KR100981343B1 (ko) | 모공 축소용 화장료 조성물 | |
KR101724529B1 (ko) | 홍해삼 추출물을 흑효모 균사체로 발효한 홍해삼 흑효모 발효액을 포함하는 화장료 조성물 | |
FR3117340A1 (fr) | Utilisation cosmétique, nutraceutique ou dermatologique d’une souche deLactobacillus crispatus et / ou d’une composition la comprenant | |
WO2015036704A1 (fr) | Utilisation cosmetique ou dermatologique d'un extrait de tapirira guyanensis | |
FR3011742A1 (fr) | Nouvel actif pour homogeneiser le vermillon des levres et compositions cosmetiques le comprenant | |
EP2229145A2 (fr) | Utilisation d'un extrait de petales de coquelicot pour la nutrition de l'epiderme | |
FR3008890B1 (fr) | Extrait de chene, composition comprenant ledit extrait et utilisations notamment cosmetiques | |
KR20180046023A (ko) | 흑효모 발효 가지씨 초음파 추출물을 함유하는 화장료 조성물 | |
KR20030086187A (ko) | 천연물을 이용한 항노화 화장료 | |
FR3003170A1 (fr) | Utilisation d'un extrait de jacinthe d'eau pour l'hydratation de la peau | |
FR3116727A1 (fr) | Composition comprenant une eau végétale de riz et une huile de son riz de Camargue et utilisations notamment en cosmétique | |
FR2967063A1 (fr) | Utilisation d'extrait de grenade comme agent raffermissant de la peau d'un sujet ayant subi une modification de poids ou un acte de chirurgie esthetique | |
FR2913198A1 (fr) | Utilisation cosmetique d'une association de biotine et de vitamine cg. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2004525474 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003758186 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003758186 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006165643 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10523333 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10523333 Country of ref document: US |